Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.

Abstract

OBJECTIVE:

To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH).

RESEARCH DESIGN AND METHODS:

In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 μg or 200 μg dasiglucagon.

RESULTS:

Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008).

CONCLUSIONS:

Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

• Authors: Casper K Nielsen, Caroline C Øhrstrøm, Urd L Kielgast, Dorte L Hansen, Bolette Hartmann, Jens J Holst, Asger Lund, Tina Vilsbøll, Filip K Knop
• Journal: Diabetes care (Diabetes Care) Vol. 45 Issue 6 Pg. 1476-1481 (06 02 2022) ISSN: 1935-5548 [Electronic] United States
• PMID: 35320361 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 by the American Diabetes Association.

Chemical References

• Blood Glucose
• Insulin
• dasiglucagon
• Glucagon

Topics

• Blood Glucose
• Blood Glucose Self-Monitoring
• Cross-Over Studies
• Double-Blind Method
• Gastric Bypass (adverse effects)
• Glucagon (analogs & derivatives)
• Humans
• Hypoglycemia (drug therapy, etiology, prevention & control)
• Insulin (therapeutic use)